Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

10 evidence topics · 18 sources

Summary

Resmetirom and semaglutide 2.4 mg are approved for noncirrhotic MASH with moderate to advanced liver fibrosis, both under accelerated approval based on improvement of MASH and fibrosis. In the MAESTRO-NASH primary analysis population of 966 patients, NASH resolution with no worsening of fibrosis occurred in 25.9% (resmetirom 80 mg) and 29.9% (100 mg) compared with 9.7% (placebo), and fibrosis improvement by at least one stage in 24.2% and 25.9% compared with 14.2%. The EASL guideline states that evidence is limited to 52-week histological data, that about 70-80 % of participants did not respond according to histological criteria, and that there is no evidence to guide when to stop treatment. In the ESSENCE interim analysis of the first 800 patients at week 72, resolution of steatohepatitis occurred in 62.9% with semaglutide and 34.3% with placebo, and reduction in fibrosis in 36.8% and 22.4%; the AASLD semaglutide update states that 37.1% of treated participants did not resolve MASH and 63.2% did not have a reduction in fibrosis, and that available data do not identify predictors of response. No FDA-approved noninvasive test diagnoses MASH with F2 to F3 or monitors response to pharmacotherapy. Resmetirom and semaglutide have not been studied in combination or compared. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription. The EASL guideline states that agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes and that no MASH-targeted pharmacotherapy can currently be recommended at the cirrhotic stage.

Other options have limits. Few patients (≤ 10%) achieve effective weight loss with structured interventions at 1 year, and fewer than half of these maintain it at 5 years; in one cohort, 88 of 293 participants (30%) lost 5% or more of their weight at week 52. Pioglitazone and vitamin E are not FDA approved for MASH, the EASL guideline does not recommend either as a MASH-targeted therapy, and in a 96-week trial in 247 adults without diabetes neither was associated with improvement in fibrosis scores; pioglitazone was associated with a mean weight gain of 4.7 kg at week 96, and its label states that thiazolidinediones cause or exacerbate congestive heart failure in some patients. The EASL guideline finds insufficient evidence to recommend SGLT2 inhibitors or metformin as MASH-targeted therapies. Metabolic surgery is not indicated solely for treatment of MASH, advanced fibrosis persisted in 47% of individuals in one post-surgery biopsy study, and in a cohort of 650 surgical patients with fibrotic NASH, 4 (0.6%) died from surgical complications within the first year.

Access and persistence are also limited. A diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population has been estimated. In one cohort, 129 of 137 patients prescribed resmetirom (94.2%) required prior authorization, 33 (24.1%) prior authorization denials required appeal, and resmetirom was dispensed on average 22.7 days after prescription; in another cohort, 13 patients (16%) discontinued resmetirom after an average of 25.5 days, 11 because of adverse events. In company market research with 100 US MASH treaters, 85% of specialists described the greatest unmet needs as lack of effective, liver-directed therapies.